Global Chronic Kidney Disease Treatment Market Size study & Forecast, by Treatment (Drug, Dialysis), by End User (Hospital, Dialysis Center, Others) and Regional Analysis, 2023-2030

Global Chronic Kidney Disease Treatment Market Size study & Forecast, by Treatment (Drug, Dialysis), by End User (Hospital, Dialysis Center, Others) and Regional Analysis, 2023-2030

Global Chronic Kidney Disease Treatment Market is valued at approximately USD 32 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 4% over the forecast period 2023-2030. A long-term disorder is known as chronic kidney disease (CKD); it is characterized by a progressive decline in kidney function. The kidneys are essential for removing waste materials, excess fluids, and toxins from the bloodstream. They also assist in controlling blood pressure, electrolyte balance, and the generation of red blood cells. CKD typically starts out gradually and progresses through a range of phases, from mild to severe, depending on the extent of renal function. The most common causes of CKD include various renal illnesses or abnormalities, diabetes, and hypertension. As a result, ""chronic kidney disease (CKD) treatment"" encompasses a range of medical interventions and techniques designed to manage and prevent the progression of kidney damage as well as the effects that are associated with it. The Chronic Kidney Disease Treatment market is expanding because of factors such as the increasing incidence of chronic kidney disease and the growing geriatric Population.

The Centres for Disease Control and Prevention (CDC) reported that 37 million Americans, or more than 1 in 7 persons, had chronic kidney disease in 2021. Similarly, as per a report by the national health portal of the Indian Government in July 2022, the prevalence of end-stage renal disease (ESRD) in India is leading to a significant rise in the number of new patients, estimated at approximately 2.2 lahks each year. Thus, the rising prevalence of kidney chronic disease across the globe is fostering the market growth. The increase in the elderly population is another important element boosting the chronic renal disease treatment market. The ageing population, which is at high risk for the onset and progression of CKD, and the rising popularity of cutting-edge treatments are predicted to further propel market expansion. For instance, the CDC reports that many patients with chronic kidney disease are 65 or older (38%), followed by those between the ages of 45 and 64 (12%), and those between the ages of 18 and 44 (6%). The Globe Bank Group estimates that there were 727 million elderly people in the globe in 2020, and that number may triple over the following three decades to reach 1.5 billion by the year 2050. Thus, the rising prevalence of geriatric population is catering the market growth. In addition, rising technological advancement and rising investment in research and development activities are creating lucrative growth in the market. However, the high cost of chronic kidney disease treatment and inadequate healthcare infrastructure stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Chronic Kidney Disease Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing factors such as rising prevelance of diseases, rising dominance of key market players, rising advancement in treatment procedure technology and more. Whereas, Asia Pacific is projected to growth at a fastest rate owing to factors such as rising prevelance of various chronic diseases, rising number of partnership and collaboration for development of advance treatment technologies, rising research and development activities and active participation of government in the market place.

Major market player included in this report are:
F. Hoffmann-La Roche Ltd
Johnson & Johnson Pvt Ltd
Fresenius SE and Co. KGaA
Teva Pharmaceutical Industries Ltd.
AstraZeneca plc
B. Braun SE
Pfizer Inc
Baxter International Inc
Becton, Dickinson and Company
AbbVie Inc.

Recent Developments in the Market:
In February 2023, The European Union approved the use of Forxiga (dapagliflozin), a medication from AstraZeneca, to treat heart failure (HF) with reduced ejection fraction (HFrEF), as well as HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).
In Aug 2022, Fresenius Medical Care, the leading provider of products and services for persons with renal illnesses worldwide, reports that the VersiPD Cycler System has received FDA approval. This next-generation portable automated peritoneal dialysis system is the smallest, lightest, and quietest dialysis cycler available in the United States.

Global Chronic Kidney Disease Treatment Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Treatment, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Treatment:
Drug
Dialysis

By End User:
Hospital
Dialysis Center
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
F. Hoffmann-La Roche Ltd
Johnson & Johnson Pvt Ltd
Fresenius SE and Co. KGaA
Teva Pharmaceutical Industries Ltd.
AstraZeneca plc
B. Braun SE
Pfizer Inc
Baxter International Inc
Becton, Dickinson and Company
AbbVie Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.